US Patent 11851655 Compositions and methods for modulating apolipoprotein (a) expression
Patent 11851655 was granted and assigned to Ionis Pharmaceuticals on December, 2023 by the United States Patent and Trademark Office.
All edits
US Patent 11851655 Compositions and methods for modulating apolipoprotein (a) expression
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
Find more entities like US Patent 11851655 Compositions and methods for modulating apolipoprotein (a) expression
